Flupenthixol Treatment for Cocaine Abusers with Schizophrenia: A Pilot Study

References

• Schneier F. R., Siris S. G. A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. J. Nerv. Mental Dis. 1987; 175: 641–652
   PubMed Web of Science ®Google Scholar
• Regier D. A., Farmer M. E., Rae D. S., et al. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the epidemiologic catchment area (ECA) study. JAMA 1990; 264: 2511–2518
   PubMed Web of Science ®Google Scholar
• Mueser K. T., Yarnold P. R., Levinson D. R., et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates, Schizophr. Bull. 1990; 16: 31–56
   Google Scholar
• Osher F. C, Drake R. E. Reversing a history of unmet needs: Approaches to care for persons with co-occurring addictive and mental disorders. Am. J. Orthopsychiatry 1996; 66: 4–11
   PubMed Web of Science ®Google Scholar
• Dixon L., Haas G., Weiden P. J., et al. Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. Am. J. Psychiatry 1991; 148: 224–230
   PubMed Web of Science ®Google Scholar
• Drake R. E., Wallach M. A. Substance abuse among the chronic mentally ill. Hosp. Community Psychiatry 1989; 40: 1041–1046
   PubMedGoogle Scholar
• Negrete J. C, Knapp W. P., Douglas D. E., et al. Cannabis affects the severity of schizophrenic symptoms: Results of a clinical survey. Psychol. Med. 1986; 16: 515–520
   PubMed Web of Science ®Google Scholar
• Brady K., Anton R., Ballenger J. C., et al. Cocaine abuse among schizophrenic patients. Am. J. Psychiatry 1990; 147: 1164–1167
   PubMed Web of Science ®Google Scholar
• Dixon L., McNary S., Lehman A. Substance abuse and family relationships of persons with severe mental illness. Am. J. Psychiatry 1995; 152: 456–458
   PubMed Web of Science ®Google Scholar
• Cournos F., Empfield M., Horwath E., et al. HIV seroprevalence among patients admitted to two psychiatric hospitals. Am. J. Psychiatry 1991; 148: 1225–1230
   PubMed Web of Science ®Google Scholar
• Miller F., Tanenbaum J. H. Drug abuse in schizophrenia. Hosp. Community Psychiatry 1989; 40: 847–849
   PubMedGoogle Scholar
• Serber M. R., Alpert M., Richardson N. A., et al. Clinical effects of recent cocaine use on patients with acute schizophrenia. Am. J. Psychiatry 1995; 152: 1464–1469
   PubMedGoogle Scholar
• Lamb H. R. Young adults chronic patients: the new drifters. Hosp. Community Psychiatry 1982; 33: 465–468
   PubMedGoogle Scholar
• Gruber A. J., Cole J. O. Antidepressant effects of flupenthixol. Pharmacotherapy 1991; 11: 450–459
   PubMedGoogle Scholar
• Carney M. W. P., Sheffield B. F. Comparison of antipsychotic depot injections in the maintenance treatment of schizophrenia. Br. J. Psychiatry 1976; 129: 476–481
   PubMed Web of Science ®Google Scholar
• Pinto R., Bannerjee A., Ghosh N. A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Acta Psychiatr. Scand. 1979; 60: 313–322
   PubMedGoogle Scholar
• Kong D. S. G., Yeo S. H. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Pharmathefapeutica 1989; 5: 371–379
   PubMedGoogle Scholar
• Trueman H. R., Valentine M. G. Flupenthixol decanoate in schizophrenia. Br. J. Psychiatry 1974; 124: 58–59
   PubMed Web of Science ®Google Scholar
• Kelly H. B., Freeman H. L., Banning B., et al. Clinical and social comparison of fluphenazine decanoate and flupenthixol decanoate in the community maintenance therapy of schizophrenia. Int. Pharmacopsychiatry 1977; 12: 54–64
   PubMedGoogle Scholar
• Haslam M. T., Bromham B. M., Schiff A. A. A comparative trial of fluphenazine decanoate and flupenthixol decanoate. Acta Psychiatr. Scand. 1975; 51: 92–100
   PubMed Web of Science ®Google Scholar
• Johnson D. A. W., Malik N. A. A double-blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia. Acta Psychiatr. Scand. 1975; 51: 257–267
   PubMed Web of Science ®Google Scholar
• Hamilton M., Card I. R., Wallis G. G., et al. A comparative trial of the decanoates of flupenthixol and fluphenazine. Psychopharmacology 1974; 64: 225–229
   Google Scholar
• Ehrmann T. S., Delva N. J., Beninger R. J. Flupenthixol in chronic schizophrenic inpatients: A controlled comparison with haloperidol. J. Clin. Psychopharmacol. 1987; 7: 173–175
   PubMedGoogle Scholar
• Farde L., Nordstrom A., Wiesel F., et al. Positron emission tomographic analysis of central Dl and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side-effects. Arch. Gen. Psychiatry 1992; 49: 538–544
   PubMed Web of Science ®Google Scholar
• Lynch M. R. Schizophrenia and the Dl receptor: Focus on negative symptoms. Prog. Neurop-sychopharmacol. Biol. Psychiatry 1992; 16: 797–832
   PubMedGoogle Scholar
• Gawin F. H., Allen D., Humblestone B. Outpatient treatment of “crack” cocaine smoking with flupenthixol decanoate. Arch. Gen. Psychiatry 1989; 46: 322–325
   PubMed Web of Science ®Google Scholar
• Gawin F. H., Khalsa-Denison M. E., Jatlow P. Flupenthixol-induced aversion to crack cocaine. N. Engl. J. Med. 1996; 334: 1340–1341
   PubMedGoogle Scholar
• First M. B., Spitzer R. L., Gibbon M., et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P Version 2.0). Biometric Research Department, New York 1995
   Google Scholar
• Kay S. R., Fiszbein A. A Positive and Negative Syndrome Scale (PANSS) Manual. Multi-Health Systems, Inc., Toronto 1992
   Google Scholar
• Simpson G. M., Angus J. W.S. A rating scale for extrapyramidal side-effects. Acta Psychiatr. Scand. 1970; 212: 11–19
   Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology. U.S. Government Printing Office, Washington, DC 1976; 534–537, DHEW Publication No. 76-338
   Google Scholar
• Beck A. T., Ward C. H., Mendelson M., et al. An inventory form measuring depression. Arch. Gen. Psychiatry 1961; 4: 561–571
   PubMed Web of Science ®Google Scholar
• Kay S. R., Fiszbein A., Opler L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261–276
   PubMed Web of Science ®Google Scholar
• Gawin F. H., Kleber H. D. Cocaine abuse treatment: An open pilot trial with lithium carbonate and desipramine. Arch. Gen. Psychiatry 1984; 41: 903–910
   PubMed Web of Science ®Google Scholar
• Halikas J. A., Kuhn K. L., Corby R., et al. The measurement of craving in cocaine patients using the Minnesota Cocaine Craving Scale. Compr. Psychiatry 1991; 32: 22–27
   PubMed Web of Science ®Google Scholar
• McHugo G. J., Drake R. E. A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. J. Nerv. Ment. Dis. 1995; 183: 762–767
   PubMed Web of Science ®Google Scholar
• Knight A., Okasha M. S., Salih M. A., et al. Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic outpatients. Br. J. Psychiatry 1979; 135: 515–528
   PubMedGoogle Scholar
• Tam W., Young J. P. R., John G., et al. A controlled comparison of flupenthixol decanoate injections and oral amitriptyline in depressed out-patients. Br. J. Psychiatry 1982; 140: 287–291
   PubMedGoogle Scholar
• Weddington W. W., Brown B. S., Haertzen C. A., et al. Changes in mood, craving, sleep during short-term abstinence reported by male cocaine addicts. Arch. Gen. Psychiatry 1990; 47: 861–868
   PubMed Web of Science ®Google Scholar
• Satel S. L., Price L. H., Palumbo J. M., et al. Clinical phenomenology and neurobiology of cocaine abstinence: A prospective inpatient study. Am. J. Psychiatry 1991; 148: 1712–1716
   PubMed Web of Science ®Google Scholar
• Lysaker P., Bell M., Beam-Goulet J., et al. Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J. Nerv. Merit. Dis. 1994; 182: 109–112
   PubMed Web of Science ®Google Scholar
• Ziedonis D., Richardson T., Lee E., et al. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol. Bull. 1992; 28: 309–314
   PubMed Web of Science ®Google Scholar
• Buckley P., Thompson P., Way L., et al. Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine therapy. Am. J. Psychiatry 1994; 151: 385–389
   PubMed Web of Science ®Google Scholar
• Contoreggi C, Cheskin L. J., Lange W. R. Acute hepatitis after clozapine administration. Am. J. Addictions 1996; 5: 5–11
   Google Scholar